# EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck

> **NCT01360827** · PHASE1 · TERMINATED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 13 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** EMD 1201081 + 5-FU + Cisplatin + Cetuximab
- **DRUG:** EMD 1201081 + 5-FU + Cisplatin + Cetuximab

## Key facts

- **NCT ID:** NCT01360827
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-08
- **Primary completion:** 2011-04
- **Final completion:** —
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Study terminated due to potential safety concerns in combination with platinum-based therapies
- **Last updated:** 2014-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01360827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01360827, "EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01360827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*